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Abstract Discrete windows of susceptibility to toxicants
have been identified for the breast, including in utero,
puberty, pregnancy, and postpartum. We tested the
hypothesis that polychlorinated biphenyls (PCBs) mea-
sured during the early postpartum predict increased risk of
maternal breast cancer diagnosed before age 50. We ana-
lyzed archived early postpartum serum samples collected
from 1959 to 1967, an average of 17 years before diagnosis
(mean diagnosis age 43 years) for 16 PCB congeners in a
nested case–control study in the Child Health and Devel-
opment Studies cohort (N = 112 cases matched to controls
on birth year). We used conditional logistic regression to
adjust for lipids, race, year, lactation, and body mass. We
observed strong breast cancer associations with three
congeners. PCB 167 was associated with a lower risk (odds
ratio (OR), 75th vs. 25th percentile = 0.2, 95 % confi-
dence interval (95 % CI) 0.1, 0.8) as was PCB 187 (OR,
75th vs. 25th percentile = 0.4, 95 % CI 0.1, 1.1). In con-
trast, PCB 203 was associated with a sixfold increased risk
(OR, 75th vs. 25th percentile = 6.3, 95 % CI 1.9, 21.7).
The net association of PCB exposure, estimated by a post-
hoc score, was nearly a threefold increase in risk (OR, 75th
vs. 25th percentile = 2.8, 95 % CI 1.1, 7.1) among women
with a higher proportion of PCB 203 in relation to the sum
of PCBs 167 and 187. Postpartum PCB exposure likely
also represents pregnancy exposure, and may predict
increased risk for early breast cancer depending on the
mixture that represents internal dose. It remains unclear
whether individual differences in exposure, response to
exposure, or both explain risk patterns observed.
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Introduction
Discrete windows of susceptibility to toxicants have been
identified for the breast, including in utero, during puberty,
and during pregnancy and postpartum [1–4]. Human
studies of breast cancer have not been able to assess the
effects of measured exposure to environmental chemicals
during windows of susceptibility for the breast [2, 5]. The
existing literature on polychlorinated biphenyls (PCBs) and
breast cancer typically has focused primarily on postmen-
opausal breast cancer [6–8]. In addition, exposure in prior
studies was largely measured in middle age or at time of
diagnosis, was variable on how PCBs were classified and
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whether individual congeners were considered, and was
based on samples obtained after PCB use was regulated [6–
8]. The literature on the pesticide DDT and breast cancer is
subject to similar limitations [9].
Findings on the relation of PCBs measured in middle
age to breast cancer are complex and have been reviewed
previously in detail (see Table 3, pp. 2872–2876 in Brody
et al. [8]). Briefly, some studies reported positive associa-
tions with individual congeners, others reported no asso-
ciations for total PCBs or any individual congeners, and
others reported negative associations with some tumor
types. The most consistent, positive findings were reported
where interaction between exposure and CYP1A1 gene
polymorphisms could be considered. Three studies found
higher PCB exposures with postmenopausal breast cancer
in combination with the CYP1A1 polymorphism, M2 type
[10–12] and another reported this association with pre-
menopausal breast cancer [13].
The present prospective study adds a unique perspective
by testing the hypothesis that exposure to PCBs, measured
during the early postpartum, is associated with increased
risk of early breast cancer. Because of the long half-life of
PCBs [14], early postpartum levels also reflect exposure
during pregnancy [15] and possibly during childhood and
adolescence. To our knowledge, this is the first study to
report on breast cancer associations in relation to measured




Subjects were participants in the Child Health and Devel-
opment Studies (CHDS), residents of the Oakland, Cali-
fornia area and members of the Kaiser Permanente Health
Plan who sought obstetric care between 1959 and 1967
[16]. Subjects voluntarily participated in the CHDS, giving
an oral informed consent for an in-person interview, col-
lection of blood specimens at several points in pregnancy
and the early postpartum, and permission for medical
record access. This study was reviewed and approved by
The Institutional Review Board of the Public Health
Institute and we have complied with all federal guidelines
governing use of human participants.
Breast cancer cases were identified by linkage to the
California Cancer Registry, and the California Vital Status
Records [17]. All names for each CHDS subject are sub-
mitted for cancer linkages using fixed (i.e. birth date, sex,
race, and name) and changeable (i.e. address and patient
record number) identifiers. A rigorous protocol is used to
verify cases, comparing fixed versus changeable identifiers
by manual review. The California Cancer Registry is
reported to be [99 % complete after a lag time of about
2 years [18].
Cases were defined as women with incident invasive or
non-invasive breast cancer diagnosed before age 50, or
deaths due to breast cancer before age 50, obtained from
linkage conducted in early 1998. There were 133 cases who
met study criteria. All members of the CHDS cohort are
additionally linked to the California Department of Motor
Vehicles (DMV) files on a regular basis to determine res-
idence history allowing us to assess their control status and
to update any name changes. All names registered with the
DMV are used in establishing a match. Simultaneous
linkage of multiple family members enhances matching.
The regular DMV matching provides a history of location
for each subject which is used to determine the population
at risk for cancer, corresponding with geographic surveil-
lance by California’s cancer registries. Subjects who can-
not be located are considered lost to follow-up at the date
of their last definitive classification as a California resident.
One control, matched exactly on birth year, was selected at
random for each case from those who were under cancer
surveillance and known to be free of breast cancer at the
age of diagnosis for the matching case. The median time to
diagnosis for cases was 17 years. The mean age at diag-
nosis was 43 years.
Serum assays
Exposure to PCBs was measured by assays of serum
samples drawn during the early postpartum period, within
1–3 days of delivery. Postpartum samples were used to
conserve valuable archived serum samples drawn in each
trimester for future studies where timed samples are
essential. PCBs have a long half-life and prior work has
established stability of organochlorine levels assayed
across all trimesters of pregnancy and the early postpartum
[15]. For this reason, postpartum levels of PCBs may
accurately rank women on their pregnancy exposure,
covering two potential vulnerable periods of susceptibility
of the breast to toxicants.
PCBs were assayed in the laboratory of Dr. Mary Wolff
[19] using modifications of methods developed previously
by Brock et al. [20]. Briefly, a polar extraction of serum
lipids is followed by a column chromatographic clean-up
and enrichment step, with analysis by gas chromatography
with electron capture detection. Limits of detection were
approximately 0.07 ng/mL for individual compounds
based on three times the standard deviation of the levels
found in the lowest quality control plasma pool [21]. When
the serum pool and blanks were considered together [22],
the limit of detection was 0.01–0.1 ng/mL; the instru-
mental limit of detection based on a peak-to-noise ratio of
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3 was 0.01–0.03 ng/mL for tetra- through hepta-chlorobi-
phenyls, using 1–1.5 mL plasma. As described previously
[23], we used all observed positive values of PCBs in
analyses, even those reported to be below the limit of
detection.
We were able to assay archived serum samples for the
PCB congeners which are shown in Table 1. These cong-
eners include those most commonly reported in prior
studies, comprised the congeners with highest concentra-
tions, or grouped by potential biological activity as previ-
ously recommended [24]. We randomly assigned the order
of samples within and across batches and analyzed case–
control pairs in the same batches to minimize differences
due to laboratory drift. The laboratory was blind as to case
or control status of the samples. Intra-batch coefficients of
variation ranged from 5 % for PCB 180 to 18 % for PCB
101. Total cholesterol and total triglycerides were mea-
sured enzymatically on the Hitachi 911 analyzer (Roche
Diagnostics, Indianapolis, IN) in a lab certified by the
Centers for Disease Control and Prevention and the
National Heart Lung and Blood Institute Lipid Standardi-
zation Program.
Statistical analysis
This report is based on 112 case–control pairs, matched on
year of birth, after excluding 2 pairs with insufficient serum
for lipid assays, 2 pairs with missing data on body mass
index, and 17 pairs where one or more member of the pair
was missing information on PCB 167, which was not
quantified in one of the assay batches. In a sensitivity
analysis, we imputed missing PCB 167 by matching on
case status and date of blood draw and assigning a PCB
value for the missing individual based on a random pick of
all matches. Results were similar (associations were of a
similar magnitude with overlapping 95 % confidence
intervals and all associations remained statistically signif-
icant, defined as p \ 0.05) whether or not the individuals
with imputed values were included. We present findings
only for individuals with non-missing data on all study
Table 1 Distribution of PCBs in breast cancer controls and cases
Classification [24] PCB Controls (N = 117) Cases (N = 123) Difference within
matched pairs
(case–control, N = 112)
Percent [ LOD
Percentile (mmol/l) Percentile (mmol/l)
25th 50th 75th 25th 50th 75th Mean (mmol/l) p value
Estrogenic 101 0.37 0.74 1.07 0.34 0.55 0.92 -0.06 0.19 89
187 0.38 0.48 0.66 0.38 0.48 0.63 -0.07 0.30 100




66 0.89 1.34 1.78 0.96 1.47 1.95 0.10 0.17 99
74 0.62 0.89 1.23 0.62 0.86 1.27 0.01 0.54 95
105 0.25 0.40 0.64 0.25 0.43 0.61 -0.01 0.92 81
118 1.19 1.62 2.02 1.19 1.53 2.11 -0.03 0.94 100
156 0.11 0.28 0.42 0.11 0.28 0.39 -0.03 0.68 64
167 0.08 0.19 0.30 0.08 0.14 0.25 -0.03 0.12 49
B. Di-ortho, limited
dioxin activity
138 1.58 2.05 2.55 1.50 2.02 2.77 -0.09 0.56 100
170 0.30 0.46 0.66 0.35 0.48 0.63 -0.01 0.74 97
Phenobarbital, CYP1A,
and CYP2B inducers
99 0.28 0.58 0.80 0.25 0.52 0.86 -0.04 0.30 83
153 1.88 2.38 3.08 1.86 2.43 3.08 -0.08 0.40 100
180 0.89 1.21 1.54 0.94 1.21 1.57 0.01 0.63 100
183 0.13 0.23 0.35 0.10 0.23 0.33 -0.03 0.32 66
203 0.21 0.30 0.42 0.23 0.35 0.47 0.02 0.20 90
203/167 ? 187 0.34 0.43 0.52 0.38 0.50 0.63 0.09 NA NA
Variable number of subjects in each group is due to missing data on one or more of the PCB congeners shown. The PCB score (PCB 203/(PCB
187 ? PCB 167)) was based on the best fitting model as described in the text, and is provided to describe the distribution of the mixture of
significant PCB predictors. p values are not presented for the PCB score because the score was created after analysis, as described in text.
p values shown are for Wilcoxon Signed Rank Test of differences (case–control) within age-matched case–control pairs
LOD limit of detection
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variables, as this is a conservative choice based on
observed values.
We performed data analysis using age-matched condi-
tional logistic regression as in our prior study of DDT and
breast cancer in this same population [25]. We began with
a full model, entering all PCBs classified by Wolff et al.
[24]. as potentially relevant to human health: Group 1
consisted of congeners detected in the CHDS serum sam-
ples that were considered to be potentially estrogenic and
persistent (PCB 101,187, 201). Group 2 consisted of
congeners detected in the CHDS serum samples that were
considered to be potentially antiestrogenic, immunotoxic,
dioxin-like: Group 2A which are non-ortho or mono-ortho
in their structure (PCB 66, 74,105,118,156,167) and Group
2B which are di-ortho and have more limited dioxin-like
activity (PCB 138 and 170). Group 3 consisted of pheno-
barbital, CYP1A and CYP2B inducers (PCB 99, 153,180,
183, 203). Congeners that had individual p [ 0.20 were
tested for removal as a group, based on a likelihood ratio
test (p \ 0.15 as the criterion). At the next step, we used a
more stringent criterion, eliminating remaining PCB terms
with individual significance probabilities [0.05. In addi-
tion to using the likelihood ratio test to test the hypothesis
that the coefficients for these terms were each 0 using the
criterion, p \ 0.15, we also examined the sign and size of
coefficients of remaining predictors before and after elim-
ination to rule out major confounding by the eliminated
predictors. Our goal was to identify the minimal number of
PCBs that predicted risk. Once the best PCB model was
identified, we examined whether further adjustment for
blood lipids (total cholesterol, total triglycerides), parity,
year of blood draw, body mass index (lower tertile, upper
tertile vs. middle tertile as the reference category) and
breast feeding following the current pregnancy altered PCB
associations with breast cancer.
To describe the net effect of PCB exposure on breast
cancer, we constructed a post-hoc score that consisted of
the ratio of the sum of PCB congener(s) associated with
higher risk of breast cancer to the sum PCB congeners
associated with lower risk as in a previous report on health
effects of PCB exposure in this population [26]. We then
examined the variation in the post-hoc score and described
its association with breast cancer in this population.
Results
Table 1 shows the distribution of PCB congeners and a
post-hoc PCB score based on the final model shown in
Table 2. In this study population, PCB congener concen-
trations and the distribution of the PCB score were highly
variable. The comparisons between cases and controls in
Table 1 show no remarkable, statistically significant
associations between single PCB congeners and breast
cancer risk, in the absence of control for other congeners.
This observation suggests that confounding would play a
role in any associations observed in multivariate models.
There were no associations between the sum of total
PCBs or with PCB groups (groups shown in Table 1) and
risk of breast cancer (data not shown). Table 2 shows
results of multivariate conditional logistic regression
models for individual PCB congeners. PCB 203 is the only
congener with a consistent and statistically significant
positive coefficient, indicating that it was associated with
increased risk of breast cancer (Table 2, both models). In
contrast, PCB 167 and PCB 187 were inversely associated
with risk of breast cancer (Table 2, both models). To check
for dose response, we also estimated associations for these
PCBs by quartile shown in Table 3. Results were largely
consistent with a monotonic trend for each congener.
Table 2 Associations of individual PCB congeners with breast can-
cer diagnosed before 50 years of age
Classification
[24]
PCB Model with all PCBs Final model
Coefficient p value Coefficient p value
Estrogenic 101 0.39 0.41



























203 6.17 0.01 4.36 0.001
In the column labeled, ‘‘Model with all PCBs’’, congeners were
entered into a single model as the first step in model selection.
Congeners PCB 203, 187, 167 118, and 105 were initially retained
based on the criterion of p \ 0.20. PCB 118 and 105 were then
removed either one at a time or together. They were deleted from the
final model by applying the likelihood ratio test where v2 = 3.81, 2df,
p = 0.15 for the test to retain both PCB 105 and PCB 118 in the
model. Both were tested for removal simultaneously because deleting
either PCB 118 or PCB 105 alone greatly affected the size of coef-
ficient for the other. There were N = 112 age-matched case–control
pairs for all models shown and all models tested. Coefficients are
reported per 1 mmol/l
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Based on the results in Tables 2 and 3, a PCB score was
constructed as the ratio of PCB 203 (positively related to
risk) to the sum of PCBs 167 and 187 (each negatively
related to risk). The PCB score was highly variable in the
cohort, ranging from 8 % PCB 203 (compared to the sum
of PCBs 187 and 167) to 131 % PCB 203. Overall for cases
and controls combined, the median of the 4th quartile
(0.67) was 2.3 times higher than the median of the 1st
quartile (0.30). Among controls, the median of the 4th
quartile of the PCB score (0.61) was 2.5 times higher than
the median of the 1st quartile of the PCB score (0.25).
Among cases, the median of the 4th quartile of the PCB
score (0.71) was 2.2 times higher than the median of the 1st
quartile of the PCB score (0.32).
Table 4 shows the net effect of exposure based on the
proportion of PCB 203 compared to the sum of PCBs 167
and 187. Women in the top 25 % of the PCB score had
nearly three times the risk of breast cancer as women in the
bottom 25 % of the PCB score. Adjustment for lipids or
other breast cancer risk factors had little effect on this
result (Table 4), nor did adjustment for the denominator of
the PCB score or adjustment for p,p0-DDT, o,p0-DDT, and
p,p0-DDE (data not shown).
Figure 1 shows the actual distribution of the within-pair
differences for the PCB score for cases versus controls in
this study sample. In the majority of case–control pairs
(62 %), the PCB score was higher among the woman who
subsequently developed breast cancer. Pairs where the case
had a higher PCB score also showed greater differences on
the PCB score than pairs where the control had a higher
score (seen in Fig. 1; compare the right side of the Y-axis
(center axis) which shows pairs where cases within the pair
had a higher PCB score to the left side of the Y-axis which
shows pairs where controls had a higher PCB score). Fig-
ure 1 is consistent with the modeling results shown in
Tables 2, 3 and 4.
Discussion
The net effect of PCB exposure in this study population
was nearly a threefold increase in breast cancer risk among
women who had a higher proportion of PCB 203 in relation
to the sum of PCB 167 and PCB 187 (75th percentile vs.
25th percentile). These results are novel, but not incon-
sistent with the prior literature on PCBs and breast cancer.
Three comprehensive reviews concluded previously that
human studies of PCBs and breast cancer, which measured
exposure in midlife, had variable findings [6–8]. Most prior
studies reported primarily on total PCBs, which are largely
determined by the PCBs found in highest concentration in
humans (PCB 153, PCB 138, PCB 118, and PCB 180). We
too found no associations for total PCBs, high
Table 3 Associations of PCB 167, 187, and 203 with breast cancer
diagnosed before 50 years of age
PCB Quartile Odds ratio (95 % CI) p value for linear trend
167 Q1 1.00 \0.04
Q2 1.09 (0.48, 2.47)
Q3 0.70 (0.27, 1.78)
Q4 0.24** (0.07, 0.79)
187 Q1 1.00 \0.02
Q2 0.94 (0.41, 2.17)
Q3 0.92 (0.36, 2.38)
Q4 0.35* (0.11, 1.14)
203 Q1 1.00 \0.001
Q2 1.21 (0.46, 3.18)
Q3 2.89** (0.98, 8.55)
Q4 6.34 (1.85, 21.73)
Each of the three PCBs is coded as quartiles, based on the distribution
in controls. Quartile 1 is the reference category and quartiles 2, 3, 4
are entered as dummy variables for each PCB shown. Associations
shown are based on a single model where quartile terms for all PCBs
are entered. P value for trend is estimated from a linear model where
all three PCBs are entered as continuous variables. N = 112 case–
control pairs
CI confidence interval, p significance probability
* p B 0.10
** p B 0.05
 p B 0.01
Table 4 Estimated net effects of PCB exposure on risk of breast
cancer before 50 years of age





Q2 1.26 (0.53, 3.00)
Q3 1.52 (0.64, 3.62)




Q2 1.23 (0.53, 3.07)
Q3 1.53 (0.64, 3.68)




and year of blood
sampling
Q1 1.00
Q2 1.36 (0.53, 3.52)
Q3 1.78 (0.70, 4.55)
Q4 2.81 (1.11, 7.09)
CI confidence interval
a A post-hoc PCB score was defined to describe the net effect of PCB
exposure in this study sample (described in text). PCB 203 was
associated with increased risk, while PCBs 167 and 187 were asso-
ciated with decreased risk (see final model, Table 2). Therefore, the
PCB score was defined as the proportion of PCB 203 relative to the
sum of PCBs 167 and 187: PCB 203/(PCB 167 ? PCB 187).
N = 112 age-matched case–control pairs for all models shown
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concentration PCBs or sums of PCBs in functional
groupings previously proposed by Wolff et al. [24]. No
prior studies reported on the independent contribution of
the three lower concentration congeners that predicted
breast cancer in this study.
It is notable that prior studies did not measure exposure
in young women, during windows of susceptibility during
early life, when the breast might be more susceptible to
endocrine disruption, including in utero, puberty, preg-
nancy, or the postpartum [1–3]. Our ability to directly
measure exposure during the early postpartum is a partic-
ular strength of this study. A recent meta-analysis of
pregnancy-associated breast cancer outcomes found that
women diagnosed with breast cancer in pregnancy, and
particularly women diagnosed postpartum, had poorer
survival [4], providing further evidence supporting the
hypothesis that pregnancy and the postpartum period are
vulnerable periods for the breast.
As PCBs are highly persistent, it is likely that post-
partum levels also reflect pregnancy levels, as suggested by
one longitudinal study that reported high correspondence
between early postpartum levels and levels across all three
trimesters of pregnancy [15]. As women were young at the
time of blood collection, it is also possible that the early
postpartum levels of PCBs reflect exposure even prior to
pregnancy, possibly during puberty, as well. This might
explain the strength of the association observed for PCB
203, a higher chlorinated compound, as compounds with
this structure tend to have longer half-lives [14].
Other strengths of this study include prospective
assessment of exposure an average of 17 years before
diagnosis, simultaneous consideration of individual PCB
congener effects, and the opportunity to observe a popu-
lation during active exposure because blood samples were
obtained before PCBs were restricted.
Our focus on breast cancer at a young age is an addi-
tional strength. Molecular studies strongly suggest that pre-
menopausal breast cancer may not share the same features
or risk factors as breast cancer diagnosed in middle age and
older [27, 28]. Our findings could lead to better under-
standing about etiology, prevention, and treatment of early
breast cancer, if the mechanisms for the associations we
observed can be validated and investigated by experimental
toxicology and molecular studies.
Our choice to estimate the net effect of exposure to
observed PCB mixtures found in our study participants is
an additional strength. While our approach will likely be
improved upon as the methods for analyzing mixed expo-
sures advances; here, we applied an empirical approach to
describe more than individual congener associations. It is
of interest that the protective associations for PCBs 187
and 167 did not overcome the stronger, deleterious asso-
ciation observed for PCB 203. There are several specula-
tive explanations for this finding, the first being that PCB
203 is a particularly strong risk factor, as evidenced by its
point estimate. Alternatively, as the higher chlorinated
PCBs are eliminated more slowly, it is possible that post-
partum levels of PCB 203 more accurately reflect exposure
even earlier in life, including accumulations in utero,
childhood and during puberty, periods of susceptibility for
the breast in addition to pregnancy and postpartum.
Limitations of our study include the possibility of
unmeasured confounding by other exposures. In particular,
we were unable to measure dioxin exposure or activity,
raising the possibility that this or other unmeasured con-
founders could have masked or accounted for the associ-
ations we report here. However, as we observed dose
response, unmeasured confounding would have to follow
the same pattern, making this alternative explanation of our
findings less likely. It is also possible that host factors that
influence the metabolism or selective excretion of various
PCB congeners underlie the associations we observed. We
used early postpartum samples to save valuable timed
serum samples during pregnancy for other studies in the
cohort. However, prior studies conducted in serum samples
of the same age found good correspondence of these per-
sistent organochlorines across all trimesters and the early
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Fig. 1 Cumulative distribution of case–control differences for the
PCB score (N = 112 age-matched case control pairs). Each point
represents one case–control pair. The points on the right side of the y-
axis (center axis) are positive values that represent pairs where the
woman who developed breast cancer had a higher PCB score
postpartum than her matched control. In a majority of pairs (62 %),
the woman who subsequently developed breast cancer had a higher
PCB score. The differential for the PCB score was also greater for
pairs where the case had a higher score than her matched control
(compare points on the right of the y-axis to points on the left of the y-
axis)
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may also reflect pregnancy exposures. Still our study can-
not establish the age or developmental period when PCB
exposure was acquired, other than establishing that expo-
sure preceded the mean age of blood collection (age
26 years). Storage of serum samples is unlikely to have
biased study results, as all samples were similarly stored.
Randomization of samples within and between batches and
inclusion of controls and cases in the same batches mini-
mized inter- and intra-batch laboratory error.
Interpretation is limited by a lack of understanding about
the potential mechanism for PCB associations observed.
The direct association between PCB 203 and early breast
cancer was sizable and significant. However, the mode of
action for PCB 203, classified as a phenobarbital (PB)
inducer [24], is unknown. A PubMed search for ‘‘PCB
203’’ returned no citations, compared to 589 citations for
‘‘PCB 153,’’ for example. The Agency for Toxic Sub-
stances and Disease Registry report on the toxic effects of
PCBs makes no specific mention of PCB 203 effects [29].
PCB 187 has been classified as potentially estrogenic
[24], but it is unclear how postpartum or pregnancy
exposure might be associated with a lower risk of breast
cancer. This study provides little information regarding the
validity of the classification of PCB 187 as estrogenic. In
our previous report on the relation of prenatal PCB expo-
sure to time to pregnancy in daughters in this same cohort
[26], we found that a longer time to pregnancy in daughters
was associated with prenatal exposure to PCB 187. The
significant associations observed for breast cancer in
mothers and time to pregnancy in daughters following
prenatal exposure to PCB 187 deserves additional study,
perhaps in experimental models or in vitro systems. It
could be of interest to characterize PCB 187 effects in the
case of low versus high endogenous levels of estrogen and
during pregnancy and postpartum in particular.
We were unable to investigate gene/PCB interactions in
this study. The absence of associations for some of the
PCBs investigated might be explained by failure to identify
susceptible sub-populations of women. Previously, asso-
ciations were more consistently observed in sub-popula-
tions characterized by variant alleles for enzymes that
metabolize PCBs (Cytochrome P4501A1 variants) [10–13].
We were also unable to characterize the receptor status of
the breast tumors in our study. We cannot account for
lactation in subsequent pregnancies. However, breast
feeding following the current pregnancy did not predict
breast cancer in this sample and was not a confounder of
PCB associations. There was no correlation between breast
feeding following the observed pregnancy and PCB 203,
187, or 167. These findings may be explained by the low
frequency of long-term breast feeding in our cohort. Rates
of lactation in this sample were low (34 %) and among
those who did breast feed, most (60 %) breast fed for
\4 months [25]. We suggest that it is unlikely that lacta-
tion in subsequent pregnancies explains our results, as
lactation behavior is highly correlated among pregnancies
[30], but this remains a possibility.
The variable distribution of PCB congeners observed in
study subjects is to be expected as the distribution of
congeners depends on source of exposure which is influ-
enced by the chemical structure of each congener. Expo-
sure also depends on the fate of the congener in the
ecosystem which ultimately forms the source of human
exposure and on the individual response to the exposure.
All these factors contribute differently to the measured
serum level [31]. In a previous report on in utero PCB
exposure and daughter’s time to pregnancy, we also found
considerable variability in the mixture of PCB congeners in
CHDS mothers [26]. In the US, total PCB levels in adipose
tissue declined steadily after 1972 when restrictions were
implemented. A decline in PCBs was also observed in
archived blood samples in Norway during the same period
[32] and in human adipose tissue in the United States [33].
However, secular trends in the mix of congeners are
unknown [33]. As the fate of individual congeners in the
environment depends on their structure, environmental
topography, and climate, and because individual charac-
teristics may determine routes of exposure, and metabolic
fate, it is unlikely that trends for individual congeners are
the same over time, or within individuals, or across geo-
graphic areas [14]. There is little human data on this topic,
but results of repeated blood sampling in a Danish cohort
provides limited support for the concept that congener
proportions vary over time: over a 5-year period
(1976–1978 vs. 1981–1983) median concentration of total
PCBs declined 11 %, but median concentration of PCB
118 declined 34 %, PCB 180 declined 4 %, and PCB 153
declined 9 %.(adapted from Hoyer, et al., Table 1, p. 179)
[34]. If congener mixture is the underlying risk factor, then
we might expect different results for epidemiological
studies, depending on place, time, age, and other individual
characteristics that might alter external and internal dose to
these compounds.
Given the variability of congener mixtures observed in
our cohort, we speculate that an underlying host factor
related to metabolism of these compounds might contribute
to the PCB associations with breast cancer that we have
observed in this study. These data do not allow us to
determine whether PCB exposure would be necessary to
trigger an effect, or whether some host factor might be
sufficient to increase breast cancer risk. Our analysis does
indicate that PCB associations observed in this study are
independent of DDT associations previously observed in
this cohort [25]. Mechanistic studies in experimental
models, or in vitro are likely to be very important to
explaining the associations we report here, and for
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explaining the human breast cancer associations previously
reported for CYP1A1 polymorphisms in relation to PCB
exposure in middle-aged women [10–13].
In summary, in this study, the mixture of PCB congeners
predicted the estimated effect of PCB exposure on risk of
breast cancer. Overall, women in this study showed a variable
distribution for the three PCB congeners that predicted breast
cancer. Women with a high proportion of PCB 203 (top 25 %
of the study population) relative to PCBs 167 and 187 had a
nearly threefold increase in subsequent risk of breast cancer,
compared to women with a lower proportion of PCB 203
(bottom 25 % of the study population). The relation of PCB
exposure to breast cancer might be clarified by additional
laboratory, experimental and human population studies that
account for timing of exposure in relation to windows of
susceptibility for the breast and for concomitant host factors.
It is likely to be particularly important to study congener
mixtures and individual response to multiple exposures. It
remains unclear whether individual differences in exposure,
response to exposure, or both explain risk patterns observed.
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